Eli Lilly CEO encouraged by Trump meeting

Says health-care overhaul should be market-based

NEW YORK •

chief executive Dave Ricks said he drew positives from President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. healthcare system.

“There’s a chance to get that right this time,” he said of Republicans’ Obamacare repeal and replace efforts, adding that the result should be a system that is market-based, increases access to medication and provides more choices for patients.

Pharmaceutical CEOs met with Trump on Tuesday at the White House to discuss drug costs, taxes on business, industry regulation and health reform. While Trump criticized the industry for high prices, he also promised to cut regulations and get new treatments to market faster. Drug and biotechnology stocks rose after the session.

During interviews with Bloomberg on Wednesday, Ricks said the CEOs tried to educate Trump about the pitfalls of governmentcontrolled drug prices, including a system with what he called “strange economic distortions” that could increase price and reduce choice. He said they commended Medicare’s drug benefit program, where third parties help negotiate prices, a process he called “aggressive.”

“I think that’s an information gap that some of the folks close to the president had,” he said. “The idea he’s floated of, ‘Hey, we’re needing more government intervention,’ we talked about the hazards of that, and our position is government intervention is what we’ve had.”

Little was said, though, about what concessions Dave Ricks, head of Indianapolis-based drugmaker Eli Lilly & Co., was one of several CEOs to meet with U.S. President Donald Trump this week to discuss drug costs, taxes on business, industry regulation and health reform. the industry might give on pricing.

“In a setting like that, we didn’t get that specific. There’s always concerns about multiple companies sitting in the same room talking about these things together,” he said.

The U.S. doesn’t directly regulate drug prices, unlike much of the rest of the globe. Setting the cost is a murky process between drugmakers, insurers and pharmacy benefit managers.

The industry agreed to give up tens of billions of dollars in new fees and discounts as part of the Affordable Care Act, to help fund coverage provisions under the law.

Ricks said he’s concerned that a new health-care overhaul under Trump could turn to drugmakers again for funding.

If Republicans repeal Obamacare, Ricks said, “it would be naive to assume that there isn’t some set of pay-fors that legislators will need and be looking for to implement the replace.”

He also called a controversial executive order limiting travel to the U.S. from seven countries “confusing” and said that Lilly was working with its employees and determining how they were affected.

Ricks said the Indianapolis-based company has focused on liberalizing visa programs for high-skill workers, such as by making it easier to convert graduate education visas to work permits.

“Look, we’re a global company, we need to operate globally and the movement of talent is a key part of our business equation,” he said.

“So we’re for national security; we also want to make sure that these policies allow us to continue to go and access global talent the way we need to.”